Anlon Healthcare Ltd
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]
- Market Cap ₹ 1,418 Cr.
- Current Price ₹ 26.7
- High / Low ₹ 37.6 / 10.3
- Stock P/E 39.8
- Book Value ₹ 4.84
- Dividend Yield 0.00 %
- ROCE 20.8 %
- ROE 18.4 %
- Face Value ₹ 2.00
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Company has high debtors of 220 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare Nifty IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 120 | 172 | 280 | |
| Sales growth | +43% | ||
| 88 | 124 | 211 | |
| Operating Profit | 32 | 48 | 68 |
| OPM % | 27% | 28% | 24% |
| 0 | 0 | 0 | |
| Interest | 4 | 4 | 4 |
| Depreciation | 2 | 2 | 3 |
| Profit before tax | 27 | 43 | 62 |
| Tax % | 24% | 32% | |
| 21 | 29 | 42 | |
| EPS in Rs | 0.51 | 0.54 | 0.68 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 91% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|
| Equity Capital | 40 | 53 | 106 |
| Reserves | 41 | 177 | 151 |
| 67 | 44 | 72 | |
| 34 | 100 | 123 | |
| Total Liabilities | 181 | 374 | 453 |
| 23 | 58 | 79 | |
| CWIP | 0 | 0 | 1 |
| Investments | 1 | 1 | 1 |
| 158 | 315 | 371 | |
| Total Assets | 181 | 374 | 453 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -22 | -59 | |
| 2 | -36 | |
| 19 | 118 | |
| Net Cash Flow | -1 | 23 |
| Free Cash Flow | -19 | -95 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -85% | -114% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 228 | 220 |
| Inventory Days | 246 | 393 |
| Days Payable | 96 | 147 |
| Cash Conversion Cycle | 377 | 467 |
| Working Capital Days | 292 | 417 |
| ROCE % | 21% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Capacity Utilization % ・Standalone data |
|
||||
| Commercialized Products count ・Standalone data |
|||||
| Customers Served count ・Standalone data |
|||||
| Installed Capacity MTPA ・Standalone data |
|||||
| API Revenue Share % ・Standalone data |
|||||
| CDMO Molecules in Development count ・Standalone data |
|||||
| DMF Filings (Cumulative) count ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Q2 FY27 earnings call audio recording uploaded on November 3, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- We have attached herewith copy of newspaper publication. Kindly take the same on your record. Thank you.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
-
Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026
- Board approved Q2 and H1 FY2026 standalone and consolidated results on October 29, 2026.
-
Board Meeting Outcome for For Consider And Approve Unaudited Standalone And Consolidated Financial Statement For The Quarter Ended September 30, 2026
- Board approved unaudited standalone and consolidated results for quarter and half year ended September 30, 2026.
Concalls
-
Nov 2026PPT REC
-
Aug 2026Transcript PPT
-
Jun 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
Business Profile:[1]
Anlon Healthcare is a chemical manufacturing company engaged in:
a) Pharmaceutical Intermediates:
High-purity intermediates used as
raw material/starting material in APIs.
b) Active Pharmaceutical Ingredients::
Raw material for finished dosage formulations (tablets, capsules, ointments, syrups, etc.), nutraceuticals, personal care, and veterinary products.
c) Custom manufacturing/CDMO:
Development and manufacturing of complex
and novel chemical compounds, including high-purity chemicals.
The company is working on three molecules
for two global innovator companies under
its CDMO/custom-manufacturing business:
- One molecule had entered validation, with commercial supplies targeted from Q3 FY27.
- The other 2 were expected to enter validation during Q2 FY27.
- Their commercialisation was targeted for Q4 FY27 or Q1 FY28.[2]